Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
China’s Fosun Gets Heparin Supplier
by Jean-François Tremblay
January 28, 2013
| A version of this story appeared in
Volume 91, Issue 4
Jiangsu Wanbang Biopharmaceuticals, a subsidiary of the Chinese generic drug firm Fosun Pharma, has bought a 51% stake in heparin producer Zaozhuang Sainuokang Biochemical. The buy will help Wanbang control the quality and cost of its dosage-form heparin products. Wanbang, Fosun claims, is China’s largest formulator of injectable heparin. But without its own in-house source of heparin, Fosun notes, Wanbang faces high risks because of “lack of control of quality and cost.” FDA recalled adulterated Chinese-made heparin in 2008 after it caused at least 81 deaths in the U.S.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter